ClinicalTrials.govpublic full text
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
nasopharyngeal cancinoma (npc), nasopharyngeal cancer, tislelizumab, pd-1 antibody, short-course, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 825004
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.